Literature DB >> 28149867

Do insights from mice imply that combined Th2 and Th17 therapies would benefit select severe asthma patients?

Matthew E Poynter1.   

Abstract

Entities:  

Year:  2016        PMID： 28149867      PMCID： PMC5233487          DOI： 10.21037/atm.2016.11.79

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  T-helper type 2-driven inflammation defines major subphenotypes of asthma.

Authors:  Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2009-05-29       Impact factor: 21.405

2.  Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.

Authors:  William W Busse; Stephen Holgate; Edward Kerwin; Yun Chon; Jingyuan Feng; Joseph Lin; Shao-Lee Lin
Journal:  Am J Respir Crit Care Med       Date:  2013-12-01       Impact factor: 21.405

3.  Humanized Anti-IL-5 Antibody Therapy.

Authors:  Marc E Rothenberg
Journal:  Cell       Date:  2016-04-21       Impact factor: 41.582

Review 4.  Animal models of allergic airways disease: where are we and where to next?

Authors:  David G Chapman; Jane E Tully; James D Nolin; Yvonne M Janssen-Heininger; Charles G Irvin
Journal:  J Cell Biochem       Date:  2014-12       Impact factor: 4.429

5.  Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.

Authors:  Erika H De Boever; Claire Ashman; Anthony P Cahn; Nicholas W Locantore; Phil Overend; Isabelle J Pouliquen; Adrian P Serone; Tracey J Wright; Mair M Jenkins; Inderpal S Panesar; Sivayogan S Thiagarajah; Sally E Wenzel
Journal:  J Allergy Clin Immunol       Date:  2014-02-28       Impact factor: 10.793

6.  Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes.

Authors:  M Nakagawa; T Terashima; Y D'yachkova; G P Bondy; J C Hogg; S F van Eeden
Journal:  Circulation       Date:  1998-11-24       Impact factor: 29.690

7.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.

Authors:  Sally Wenzel; Mario Castro; Jonathan Corren; Jorge Maspero; Lin Wang; Bingzhi Zhang; Gianluca Pirozzi; E Rand Sutherland; Robert R Evans; Vijay N Joish; Laurent Eckert; Neil M H Graham; Neil Stahl; George D Yancopoulos; Mariana Louis-Tisserand; Ariel Teper
Journal:  Lancet       Date:  2016-04-27       Impact factor: 79.321

8.  TH17 cells mediate steroid-resistant airway inflammation and airway hyperresponsiveness in mice.

Authors:  Laura McKinley; John F Alcorn; Alanna Peterson; Rachel B Dupont; Shernaaz Kapadia; Alison Logar; Adam Henry; Charles G Irvin; Jon D Piganelli; Anuradha Ray; Jay K Kolls
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids.

Authors:  Prescott G Woodruff; Homer A Boushey; Gregory M Dolganov; Chris S Barker; Yee Hwa Yang; Samantha Donnelly; Almut Ellwanger; Sukhvinder S Sidhu; Trang P Dao-Pick; Carlos Pantoja; David J Erle; Keith R Yamamoto; John V Fahy
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-26       Impact factor: 11.205

10.  Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.

Authors:  Nicola A Hanania; Michael Noonan; Jonathan Corren; Phillip Korenblat; Yanan Zheng; Saloumeh K Fischer; Melissa Cheu; Wendy S Putnam; Elaine Murray; Heleen Scheerens; Cecile T J Holweg; Romeo Maciuca; Sarah Gray; Ramona Doyle; Dana McClintock; Julie Olsson; John G Matthews; Karl Yen
Journal:  Thorax       Date:  2015-05-22       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.